Mooney E F, Dye J F, Guillou P J, Monson J R
Academic Surgical Unit, St Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London, UK.
Br J Surg. 1993 Oct;80(10):1259-61. doi: 10.1002/bjs.1800801012.
Multidrug-resistant (MDR+) cancer cells have the ability to grow in the presence of cytotoxic concentrations of antineoplastic drugs as a result of possessing the transmembrane drug efflux pump p-glycoprotein. The MDR+ colonic cancer cell line LoVoDx (derived from the drug-sensitive line LoVo) was tested for sensitivity to lymphokine-activated killer (LAK) cell-mediated toxicity. LAK cells were cultured from patients with colonic cancer and from matched controls with benign disorders. LAK cells from patients with cancer were as effective as those from controls in mediating cytotoxicity. The MDR+ cell line was significantly more sensitive to LAK cell-mediated cell killing than its parental drug-sensitive line LoVo (P < 0.05). These results indicate a possible role for adoptive immunotherapy in MDR+ tumours expressing p-glycoprotein.
多药耐药（MDR+）癌细胞由于拥有跨膜药物外排泵P-糖蛋白，因而能够在细胞毒性浓度的抗肿瘤药物存在的情况下生长。对多药耐药的结肠癌细胞系LoVoDx（源自药物敏感细胞系LoVo）进行了对淋巴因子激活的杀伤（LAK）细胞介导毒性的敏感性测试。LAK细胞取自结肠癌患者以及匹配的良性疾病对照者并进行培养。癌症患者的LAK细胞在介导细胞毒性方面与对照者的LAK细胞一样有效。与亲代药物敏感细胞系LoVo相比，MDR+细胞系对LAK细胞介导的细胞杀伤更为敏感（P<0.05）。这些结果表明过继性免疫疗法在表达P-糖蛋白的MDR+肿瘤中可能发挥作用。
